

AMENDMENTS TO THE CLAIMS

1-19. (Canceled)

20. (Previously Presented). A method of treating depression in a patient who failed to respond to initial treatment with a selective serotonin reuptake inhibitor other than escitalopram, the method comprising administering a pharmaceutically effective amount of escitalopram or a pharmaceutically acceptable salt thereof to the patient.

21. (Previously Presented) The method of claim 20, wherein the pharmaceutically effective amount is a daily dose administered to obtain an effect in the patient after one week.

22. (Previously Presented) The method of claim 20, wherein the pharmaceutically effective amount is a daily dose of 10 mg or less of escitalopram or a pharmaceutically acceptable salt thereof to the patient.

23. (Previously Presented) The method of claim 22, wherein the daily dose is 10 mg of escitalopram or a pharmaceutically acceptable salt thereof.

24. (Previously Presented) The method of claim 22, wherein the daily dose is 7.5 mg or less of escitalopram or a pharmaceutically acceptable salt thereof.

25. (Previously Presented) The method of claim 24, wherein the daily dose is 7.5 mg of escitalopram or a pharmaceutically acceptable salt thereof.

26. (Previously Presented) The method of claim 24, wherein the daily dose is 5 mg of escitalopram or a pharmaceutically acceptable salt thereof.

27. (Previously Presented) The method of claim 20, wherein the pharmaceutically acceptable salt is an oxalate salt.

28. (Previously Presented) The method of claim 21, wherein the pharmaceutically acceptable salt is an oxalate salt.

29. (Previously Presented) The method of claim 22, wherein the pharmaceutically acceptable salt is an oxalate salt.
30. (Previously Presented) The method of claim 23, wherein the pharmaceutically acceptable salt is an oxalate salt.
31. (Previously Presented) The method of claim 24, wherein the pharmaceutically acceptable salt is an oxalate salt.
32. (Previously Presented) The method of claim 25, wherein the pharmaceutically acceptable salt is an oxalate salt.
33. (Previously Presented) The method of claim 26, wherein the pharmaceutically acceptable salt is an oxalate salt.
34. (Previously Presented) The method of claim 27, wherein the pharmaceutically acceptable salt is a crystalline oxalate salt.
35. (Previously Presented) The method of claim 28, wherein the pharmaceutically acceptable salt is a crystalline oxalate salt.
36. (Previously Presented) The method of claim 29, wherein the pharmaceutically acceptable salt is a crystalline oxalate salt.
37. (Previously Presented) The method of claim 30, wherein the pharmaceutically acceptable salt is a crystalline oxalate salt.
38. (Previously Presented) The method of claim 31, wherein the pharmaceutically acceptable salt is a crystalline oxalate salt.
39. (Previously Presented) The method of claim 32, wherein the pharmaceutically acceptable salt is a crystalline oxalate salt.

40. (Previously Presented) The method of claim 33, wherein the pharmaceutically acceptable salt is a crystalline oxalate salt.
41. (New) The method of claim 20, wherein the patient failed to respond to initial treatment with the selective serotonin reuptake inhibitor citalopram.
42. (New) The method of claim 23, wherein the patient failed to respond to initial treatment with the selective serotonin reuptake inhibitor citalopram.
43. (New) The method of claim 27, wherein the patient failed to respond to initial treatment with the selective serotonin reuptake inhibitor citalopram.
44. (New) The method of claim 30, wherein the patient failed to respond to initial treatment with the selective serotonin reuptake inhibitor citalopram.